Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA Turns Back New Indication For Rivaroxaban To Prevent Stent Thrombosis In ACS Patients
FDA Turns Back New Indication For Rivaroxaban To Prevent Stent Thrombosis In ACS Patients
FDA Turns Back New Indication For Rivaroxaban To Prevent Stent Thrombosis In ACS Patients
Submitted by
moderatorj
on June 29, 2013 - 12:25pm
Source:
Forbes
News Tags:
FDA
rivaroxaban
stent
thrombosis
Headline:
FDA Turns Back New Indication For Rivaroxaban To Prevent Stent Thrombosis In ACS Patients
Do Not Allow Advertisers to Use My Personal information
